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Abstract: Two constructs encoding the human m-opioid
receptor (hMOR) fused at its C terminus to either one of
two Ga subunits, Gao1 (hMOR–Gao1) and Gai2 (hMOR–
Gai2), were expressed in Escherichia coli at levels suit-
able for pharmacological studies (0.4–0.5 pmol/mg). Re-
ceptors fused to Gao1 or to Gai2 maintained high-affinity
binding of the antagonist diprenorphine. Affinities of the
m-selective agonists morphine, [D-Ala2,N-Me-Phe4,Gly5-
ol]enkephalin (DAMGO), and endomorphins as well as
their potencies and intrinsic activities in stimulating
guanosine 59-O-(3-[35S]thiotriphosphate) ([35S]GTPgS)
binding were assessed in the presence of added purified
Gbg subunits. Both fusion proteins displayed high-affinity
agonist binding and agonist-stimulated [35S]GTPgS bind-
ing. In the presence of Gbg dimers, the affinities of
DAMGO and endomorphin-1 and -2 were higher at
hMOR-Gai2 than at hMOR–Gao1, whereas morphine dis-
played similar affinities at the two chimeras. Potencies of
the four agonists in stimulating [35S]GTPgS binding at
hMOR–Gao1 were similar, whereas at hMOR-Gai2, endo-
morphin-1 and morphine were more potent than DAMGO
and endomorphin-2. The intrinsic activities of the four
agonists at the two fusion constructs were similar. The
results confirm hMOR coupling to Gao1 and Gai2 and
support the hypothesis of the existence of multiple re-
ceptor conformational states, depending on the nature of
the G protein to which it is coupled. Key Words: G
protein-coupled receptors—Receptor–G protein fusion—
m-Opioid receptor—Escherichia coli—Pharmacology.
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Opioid receptors and their endogenous ligands form a
neuromodulatory system that is involved in stress-in-
duced analgesia, regulation of emotional responses and
self-reward, and controls of neuroendocrine physiology
and autonomic functions such as respiration, blood pres-
sure, and gastrointestinal motility. According to their
pharmacological properties, opioid receptors are classi-
fied into three subtypes:d, m, and k, each possessing
distinct ligand selectivity profiles. Them subtype in
particular is the target of morphine, an alkaloid with
analgesic and psychotropic effects.
As members of the large family of G protein-coupled
receptors (GPCRs), opioid receptors exert their actions
through heterotrimeric G proteins (Childers, 1993). The
inhibitory effect of opioid ligands on adenylyl cyclase
and their activating effect on inward rectifying K1 chan-
nels are mediated by a pertussis toxin-sensitive mecha-
nism, which suggests coupling of the receptors to Gi/o
proteins (North, 1993; Kieffer, 1995; Satoh and Minami,
1995). For a more precise identification of the Ga protein
subtypes activated on binding of opioid agonists, one
approach combined azidoanilido [32P]GTP labeling of
activated G proteins with their subsequent immunopre-
cipitation with subtype-specific antibodies (Laugwitz
et al., 1993; Prather et al., 1994, 1995; Chakrabarti et al.,
1995; Law and Reisine, 1997). Other methods were
based on coexpression or in vitro reconstitution of the
receptor and distinct Ga subunits (Chan et al., 1995) or
on specific blocking of one Ga subtype using antibodies
directed against it (Murthy and Makhlouf, 1996).
These different approaches led to the conclusion that
opioid receptors do not distinguish among the different
Gai/o subtypes. However, in vivo down-regulation of
individual Ga subtypes using antisense oligode-
oxynucleotides provided evidence thatm- and d-opioid
receptors preferentially signal through Gai2 and Gaz
(Sanchez-Blazquez et al., 1999).
To investigate the G protein-coupling properties of the
m-opioid receptor and the impact of the different G
protein subtypes on the pharmacological properties of
the receptor, we undertook expression inEscherichia
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coli of the humanm-opioid receptor (hMOR) as a fusion
protein to either one of two putative cognate Ga sub-
units, Gao1 and Gai2. Receptor–Ga chimeras were de-
veloped as tools for studying interactions between a large
array of receptors and G proteins (review by Seifert et al.,
1999a). The present report is the first application of the
receptor–Ga chimera strategy to the study of them-opi-
oid receptor. This strategy takes advantage of the main
features of the receptor–Ga fusion proteins, namely, the
opportunity to study a defined receptor–G protein couple
under a defined 1:1 receptor:G protein stoichiometry.
This is particularly true in a prokaryotic environment,
which is devoid of endogenous GPCR or G protein
homologues. The present study is also the first report of




Plasmid pMalp2 was from New England Biolabs. Rat Go1
and Gai2 cDNAs were kindly provided by Dr. Randall Reed
(Howard Hughes Medical Institute, Johns Hopkins University
School of Medicine, Baltimore, MD, U.S.A.) (Jones and Reed,
1987). hMOR cDNA was a gift of Dr. Lei Yu (Indiana State
University, Terre Haute, IN, U.S.A.). Restriction endonucle-
ases, DNA modification enzymes, and polyclonal anti-maltose
binding protein (anti-MBP) antibody were from New England
Biolabs. Anti-Gao and -Gai2 monoclonal antibodies were from
Neomarkers. Anti-rabbit peroxidase-conjugated secondary an-
tibody and the ECL Plus detection kit were purchased from
Amersham. [D-Ala2,N-Me-Phe4,Gly5-ol]Enkephalin (DAMGO),
naloxone, guanosine 59-O-(3-thiotriphosphate) (GTPgS), and
GDP were from Sigma. Endomorphin-1 and -2 were synthesized
at IGBMC (Strasbourg, France). [35S]GTPgS was from Amer-
sham. 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesul-
fonate (CHAPS) was from Fluka. All other analytical-grade chem-
icals were from Sigma.
Strains
Strain XL1Blue was used for cloning. Strain JM101 was
used as the recipient of expression vectors.
Construction of expression vectors
The gene encoding the hMOR was isolated from human
brain (Mestek et al., 1995). The MBP–hMOR construct was
described elsewhere (Stanasila et al., 1999). The C-terminal
fragment of hMOR cDNA starting at theBamHI site (600 bp)
was PCR-amplified and subcloned as aBamHI–XbaI fragment
into the high-copy number pMalp2–hMOR expression vector
(Stanasila et al., 1999) to suppress the UAA stop codon. Gao1
and Gai2 cDNAs were PCR-amplified and subcloned into the
XbaI site of the newly generated pMalp2–hMOR vector. A
six-amino acid spacer was introduced between the hMOR and
the Ga subunit fused downstream of the receptor, to allow for
a flexible junction between the two proteins. The sequence of
the junction between hMOR and Ga cDNAs in the resulting
fusion proteins was as follows: hMOR TCT AGA GGT GCA
CAT ATG Gao1/Gai2, i.e., hMOR SRGAHM Gao1/Gai2.
Cloning was done according to standard techniques. All con-
structs were sequenced to check for the absence of PCR-
introduced mutations. Fusion proteins were expressed under the
control of thetac promoter. Liquid cultures were inoculated at
a 1:100 dilution with an overnight preculture issued from a
single colony on an agar plate. Cultures were grown at 20°C in
LB medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl)
supplemented with 100 mg/L ampicillin. Expression of the
fusion proteins was induced by addition of 0.5 mg/L isopropyl
thiogalactoside when the culture had reached an OD600 of 0.5.
Ligand binding assays
Bacteria were harvested 5 h after induction and pelleted at
3,400g for 15 min at 4°C. Bacterial membrane preparation was
done as described (Stanasila et al., 1999). Protein concentration
was estimated using the assay of Bradford (1976).
For saturation binding assays, aliquots of 23 109 intact cells
or of 50 mg of membrane proteins were incubated for 1 h at
20°C in the presence of various concentrations of [3H]diprenor-
phine in a final volume of 0.5 ml of TE buffer [50 mM Tris (pH
7.4) and 1 mM EDTA]. Competition binding was performed on
50-mg aliquots of membrane proteins, incubated at 20°C for 1 h
in the presence of 2 nM [3H]diprenorphine and various con-
centrations of agonists in a final volume of 125ml of TEM [50
mM Tris-HCl (pH 7.4), 1 mM EDTA, and 10 mM MgCl2].
Nonspecific binding was determined in the presence of 1025 M
naloxone. Reversal of high-affinity agonist binding was
achieved in the presence of 100mM GTPgS. Separation of
bound from free ligand was achieved by rapid filtration through
GF/B filters pretreated with 0.1% polyethylenimine, followed
by three washes with ice-cold 50 mM Tris-HCl (pH 7.4) on a
Brandel cell harvester. Bound radioactivity was determined by
scintillation counting.
Purification of bovine brain Gbg subunits
Bovine brain Gbg subunits were purified as described (Tay-
lor et al., 1996) and stored at 1.6 mg/ml in a buffer containing
50 mM Tris, 5 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol,
100 mM NaCl, and 0.5% cholate, pH 7.6.
Reconstitution with purified Gbg subunits
Membrane proteins from bacteria expressing hMOR–Ga
fusion proteins were incubated at a concentration of 2mg/ml in
TEMC [50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM
MgCl2, and 5 mM CHAPS] in the presence or absence of
purified Gbg subunits at a concentration of 200 nM. After
vigorous vortex-mixing, the incubation was left to proceed for
1 h on ice. Aliquots of membrane proteins were then diluted
five times with TEM and used for ligand competition binding
or [35S]GTPgS binding assays.
[35S]GTPgS binding assays
Aliquots of bacterial membrane proteins containing the
equivalent of 25 fmol of receptor sites (50 and 65mg of
membrane proteins for bacteria expressing MBP–hMOR–Gao1
and MBP–hMOR–Gai2, respectively) preincubated in TEMC
in the presence or absence of purified Gbg subunits were
incubated for 30 min at 20°C in binding buffer (TEM, 10mM
GDP, and 1 nM [35S]GTPgS) with various concentrations of
agonists in a final volume of 125ml. Reversal of agonist-
induced binding was achieved in the presence of 53 1025 M
naloxone. Separation of bound from free [35S]GTPgS was
performed by rapid filtration through GF/B filters and three
washes with ice-cold 50 mM Tris-HCl, pH 7.4. Bound radio-
activity was determined by scintillation counting.
Immunodetection of the expressed proteins
One-milliliter samples of induced bacterial cultures were
spun down, and the bacterial pellets were used for immunode-
tection of expression. Fusion proteins were detected after so-
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dium dodecyl sulfate–polyacrylamide gel electrophoresis on
10% acrylamide gels and transferred onto Immobilon mem-
branes (Millipore) by means of anti-MBP polyclonal antibodies
or anti-Gao and anti-Gai2 monoclonal antibodies, at a dilution
of 1:10,000 and 1:200, respectively. Western blots were devel-
oped using peroxidase-conjugated anti-rabbit and anti-mouse
IgG, respectively, and the chemiluminescence ECL Plus detec-
tion kit.
Data treatment
Binding data were analyzed using PRISM software (Graph-
Pad, San Diego, CA, U.S.A.). Statistical significance of the data
was assessed with the pairedt test.
RESULTS
Expression of receptor–Ga fusion proteins
For expression of hMOR–Ga fusion proteins we used
the conditions established as optimal for the expression
of human opioid receptors in bacteria (Stanasila et al.,
1999). The hMOR was fused at its N terminus to the
soluble periplasmic MBP, andE. coli strain JM101 was
chosen for expression of the recombinant proteins. Im-
munodetection using the anti-MBP antiserum (Fig. 1a)
revealed the presence of protein bands compatible with
the expected molecular mass of the MBP–hMOR–Ga
fusion proteins (;127 kDa). Several lower-molecular-
mass bands were also present and probably represented
degradation products. Monoclonal antibodies directed
against Gao and Gai2 (Fig. 1b) identified a protein band
of apparent molecular mass of 120 kDa, which was
lacking in the control (bacteria expressing MBP–
hMOR). Nonspecific detection of several protein bands
was equally present. The bands revealed by anti-MBP
and anti-Ga antibodies coincided, thus confirming ex-
pression of full-length MBP–hMOR–Ga fusion proteins.
The fused receptor was able to bind the nonselective
opioid antagonist [3H]diprenorphine with high affinity:
KD values were 0.48, 0.55, and 0.66 nM for the MBP–
hMOR–Gao1, MBP–hMOR–Gai2, and MBP–hMOR
constructs, respectively. The number of MBP–hMOR–
Gao1 and MBP–hMOR–Gai2 binding sites estimated by
saturation [3H]diprenorphine binding was 30 (0.53
pmol/mg of membrane protein) and 23 receptors per cell
(0.4 pmol/mg of membrane protein), respectively. These
values were comparable to the level obtained for MBP–
hMOR (Stanasila et al., 1999). Three independent exper-
iments performed in duplicate gave consistent results
(data not shown).
MBP–hMOR–Gao1, MBP–hMOR–Gai2, and MBP–
hMOR fusion proteins will be hereafter referred to as
hMOR–Gao1, hMOR–Gai2, and hMOR, respectively.
Reconstitution of high-affinity agonist binding
We investigated coupling between the hMOR and the
two selected Ga subtypes, Gao1 and Gai2, within the
receptor–Ga fusion protein and the role played by added
Gbg subunits in this interaction. Competition binding
experiments were performed to study the ability of var-
ious m-selective agonists to displace [3H]diprenorphine
binding to hMOR fused to Gao1 and Gai2. We chose four
m-selective agonists, including morphine, DAMGO, and
the recently isolated endogenousm-agonists endomor-
phin-1 and endomorphin-2 (Zadina et al., 1997). The
fusion proteins were reconstituted in CHAPS with puri-
fied bovine brain Gbg subunits in large molar excess (the
receptor–Ga:Gbg molar ratio was set at 1:250) or were
subjected to mock reconstitution in CHAPS only. Com-
petition curves were fitted to a one- or two-site compe-
tition model by nonlinear regression, andKi values were
calculated for the low- and high-affinity binding sites.
Control competition binding experiments were per-
formed onE. coli-expressed hMOR. To check for the
presence of contaminating Ga subunits in the Gbg dimer
preparation, achievement of high-affinity DAMGO bind-
ing was followed after reconstitution of C6 glioma cell
FIG. 1. a: Immunodetection of E. coli-expressed hMOR con-
structs using anti-MBP polyclonal antibodies. Samples were
taken from isopropyl thiogalactoside-induced cultures of JM101
bacteria, wild-type (lane 4) or harboring plasmids that encoded
MBP–hMOR–Gai2 (lane 1), MBP–hMOR–Gao1 (lane 2), or MBP–
hMOR (lane 3). Arrows indicate the position of the MBP–
hMOR–Ga fusion proteins (;127 kDa) and of MBP–hMOR (;87
kDa). The higher-molecular-weight band detected in lane 3 pos-
sibly represents MBP–hMOR dimers (Stanasila et al., 1999). b:
Immunodetection of E. coli-expressed, hMOR–Ga fusion pro-
teins using anti-Ga monoclonal antibodies. Lanes 1 and 2, anti-
Gao antibody; lanes 3 and 4, anti-Gai2 antibody. Samples were
taken from isopropyl thiogalactoside-induced cultures of JM101
bacteria harboring plasmids that encoded MBP–hMOR–Gai2
(lane 2), MBP–hMOR–Gao1 (lane 4), and MBP–hMOR (lanes 1
and 3). The arrow indicates the position of the receptor–Ga
fusion proteins (;127 kDa). The upper bands distinguishable in
lanes 2 and 4 might represent MBP–hMOR–Ga protein oli-
gomers (Stanasila et al., 1999).
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membranes constitutively expressing them-opioid recep-
tor with Gbg dimers and/or purified Gai1 subunits
(W. K. Lim and R. R. Neubig, manuscript submitted).
No significant increase in [3H]DAMGO binding was
observed with either Ga or Gbg subunits alone, whereas
high-affinity binding could be restored by reconstituting
the receptor with both Ga and Gbg. This showed that the
Ga contamination of the Gbg preparation, if present at
all, was negligible.
As described previously (Stanasila et al., 1999), com-
petition binding ofm-opioid agonists atE. coli-expressed
hMOR showed only the presence of a low-affinity site.
The binding properties of these agonists at the
hMOR–Ga fusion proteins were significantly different.
In the absence of Gbg subunits, competition binding
experiments with all four agonists on receptor–Gai2 and
with DAMGO and morphine on receptor–Gao1 showed
that two populations of binding sites, of high and low
affinity, were present. However, binding of endomor-
phin-1 and -2 to hMOR-Gao1 fitted best a one-site com-
petition model (data not shown). Figure 2 displays the
competition curves obtained with each agonist on the
two receptor–Ga fusion proteins after reconstitution with
purified Gbg subunits, as compared with hMOR alone.
High-affinity binding could be reversed by addition of
excess GTPgS, confirming that the increase in agonist
affinity was due to receptor coupling to the fused Ga
subunit. As a rule, data from experiments performed on
receptor–Ga fusion proteins in the absence of GTPgS
fitted better a two-site competition model, whereas data
from control experiments in the presence of excess
GTPgS matched a one-site competition model.
Table 1 showsKi values calculated for the high- and
low-affinity binding sites of each of the four agonists
tested on the two receptor–Ga fusion proteins, in the
absence of Gbg or reconstituted with purified Gbg sub-
units. Differences could be detected in the behavior of
the two receptor fusion proteins toward agonists in the
absence of Gbg subunits. DAMGO and morphine de-
tected the presence of two receptor populations at both
hMOR–Gao1 and hMOR–Gai2; their binding at the high-
affinity as well as the low-affinity sites at the two recep-
tor–Ga chimeras was characterized by similarKi values,
irrespective of the nature of the fused Ga subunit. Bind-
ing of endomorphin-1 and -2 at hMOR–Gao1 was best
fitted to a one-site competition model representing low-
affinity binding. Yet, binding of endomorphins at
hMOR–Gai2 could be fitted to a two-site competition
FIG. 2. Competition binding experiments on receptor–Ga fusion proteins reconstituted with Gbg subunits. Curves represent [3H]di-
prenorphine competition by (a) DAMGO, (b) endomorphin-1, (c) endomorphin-2, and (d) morphine on bacterial membranes preincubated
with 200 nM Gbg. The curves were fitted to a two- or one-site competition model using the program PRISM. Reversal of high-affinity
agonist binding was performed in the presence of 100 mM GTPgS. Nonspecific binding was determined in the presence of 1025 M
naloxone. Data are mean 6 SEM (bars) values of three independent experiments performed in duplicate.
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model, corresponding to a mixed population of high- and
low-affinity binding sites.Ki values of all four agonists at
the low-affinity site were in agreement with values ob-
tained onE. coli-expressed hMOR.
After addition of Gbg subunits, the binding of the two
endomorphins on hMOR–Gao1 could detect the presence
of a second population, composed of high-affinity bind-
ing sites. Ki values for the high-affinity binding of
DAMGO and endomorphins at hMOR–Gai2, but not at
hMOR–Gao1, were significantly decreased. Morphine
constituted an exception as its affinity for hMOR–Gai2
remained unaffected by addition of Gbg. As expected,
addition of Gbg did not significantly affectKi values
corresponding to binding at the low-affinity sites at any
one receptor–Ga fusion.
Reconstitution of the receptor–Ga fusion proteins
with purified Gbg dimers underscored differences in the
pharmacological properties conferred on the receptor by
the presence of the different Ga subunits. A comparison
of Ki values for high-affinity binding on hMOR–Gao1
and hMOR–Gai2 in the presence of Gbg revealed dif-
ferences in the behavior of the four agonists. Whereas
morphine displayed similar affinities for the two recep-
tor–Ga fusion proteins, the other three agonists had
significantly higher affinities for hMOR–Gai2 than for
hMOR-Gao1. The selectivity factor, defined as the ratio
between the twoKi values corresponding to binding at
the high-affinity site of hMOR–Gao1 and hMOR–Gai2,
was 10, 17, 17, and 1 for DAMGO, endomorphin-1,
endomorphin-2, and morphine, respectively.
[35S]GTPgS binding activity
To assess further the functionality of the receptor–Ga
protein fusion proteins, we studied agonist stimulation of
[35S]GTPgS binding on the fused Ga subunit. The time
course of [35S]GTPgS binding on the two receptor–Ga
chimeras in the absence of agonist and Gbg subunits
showed significant (p , 0.01) basal binding activity of
the hMOR–Gao1, but not hMOR–Gai2, fusion protein as
compared with the hMOR control (Fig. 3). Reconstitu-
tion with purified Gbg subunits before [35S]GTPgS
binding assay generated a stronger signal at both recep-
tor–Ga fusion proteins. After addition of Gbg subunits,
the basal [35S]GTPgS binding activity at hMOR–Gai2
was also increased to values significantly above the
hMOR control (p , 0.05). Lack of known inverse ago-
nists for them-opioid receptor subtype prevented further
investigation of whether the presence of the receptor was
TABLE 1. Competition binding in the absence and in the presence of Gbg subunits
DAMGO Endomorphin-1 Endomorphin-2 Morphine
2 Gbg 1 Gbg 2 Gbg 1 Gbg 2 Gbg 1 Gbg 2 Gbg 1 Gbg
hMOR–Gao1
High-affinity 26 1 16 0.2 — 56 0.4 — 16 0.2 0.86 0.4 0.26 0.04
Low-affinity 1106 50 406 8 306 8a 2006 40 906 10a 1706 10 1806 40 1006 10
hMOR–Gai2
High-affinity 76 3 0.16 0.04b,c 116 5 0.36 0.2b,c 186 9 0.066 0.002b,c 0.46 0.2 0.26 0.06
Low-affinity 2306 120 336 2 2506 140 1206 10 4106 160 706 10 1706 50 1806 20
hMORa 506 20 1706 90 1006 20 2006 30
Data are mean6 SEM Ki values (in nM) of [
3H]diprenorphine displacement by agonists on bacterial membranes in the absence of Gbg r
reconstituted with 200 nM purified Gbg subunits from three independent experiments performed in duplicate.
aAccording to a one-site competition model.
bSignificantly different from theKi value for high-affinity binding obtained in the absence of Gbg ( p , 0.001).
cSignificantly different from the corresponding value at hMOR–Gao1 ( p , 0.001).
FIG. 3. Time course of [35S]GTPgS binding in the absence of
agonist. The concentration of receptor sites in each aliquot was
0.2 nM. Data are mean 6 SEM (bars) values, in fmol of
[35S]GTPgS bound/mg of membrane protein, of three indepen-
dent experiments performed in duplicate. a: [35S]GTPgS binding
at hMOR–Gao1. *p , 0.05, significantly different from values
obtained in the absence of Gbg subunits; **p , 0.01, signifi-
cantly different from hMOR control values. b: [35S]GTPgS at
hMOR–Gai2. *p , 0.05, significantly different from hMOR control
values.
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in any way responsible for this apparent constitutive
activity or whether it was solely due to basal [35S]GTPgS
binding at the Ga subunits.
Figure 4 displays dose–response curves of hMOR–
Gao1 and hMOR–Gai2 in the presence of Gbg subunits,
at various concentrations of agonist, ranging from 1029
to 1025 M. All four agonists tested were able to stimulate
[35S]GTPgS binding on both receptor–Ga fusion pro-
teins. DAMGO, endomorphins, and morphine displayed
comparable potencies in stimulating [35S]GTPgS bind-
ing at hMOR–Gao1. In contrast, at hMOR–Gai2, endo-
morphin-1 and morphine were significantly more potent
than DAMGO and endomorphin-2 in stimulating
[35S]GTPgS binding (p , 0.05; Table 2).
Figure 5 shows maximal levels of stimulation of
[35S]GTPgS binding reached with the four agonists on
the two receptor–Ga fusion proteins after reconstitution
with purified Gbg dimers. Intrinsic activities of the four
agonists tested were similar at any one receptor–Ga
fusion protein. Agonist-induced [35S]GTPgS binding
could in each case be displaced by an excess of the
nonselective opioid antagonist naloxone. Reversal of ag-
onist-induced [35S]GTPgS binding in the presence of
naloxone was not complete, probably owing to the fact
that in our experimental conditions the excess of nalox-
one over the agonist was only fivefold. The magnitude of
the [35S]GTPgS binding signal was low: The fraction of
the hMOR–Ga population that bound [35S]GTPgS in the
presence of 1025 M agonist amounted to 14–15% and
11–12% of the total receptor sites in the case of hMOR–
Gao1 and hMOR–Gai2, respectively. This suggests that
all the receptor–Ga molecules that were able to bind
ligands were not equally functional in terms of Ga acti-
vation. This could be due to the partial degradation of the
fusion proteins, as suggested by the presence of a band of
;80 kDa detected by the anti-MBP antiserum that could
correspond to an MBP–hMOR product after cleavage of
the Ga subunit (Fig. 1). This supposition is reinforced by
the fact that the 80-kDa band was not detected by
anti-Ga antibodies.
DISCUSSION
We have previously shown that human opioid recep-
tors expressed inE. coli are able to bind opioid ligands
and that high-affinity binding of agonists can be recon-
stituted by addition of purified trimeric G proteins (Sta-
nasila et al., 1999). Here we report expression inE. coli
FIG. 4. Concentration-dependent stimulation of [35S]GTPgS
binding by m-opioid agonists: (a) hMOR-Gao1 and (b) hMOR–
Gai2. The concentration of receptor sites in each aliquot was 0.2
nM. Data are mean 6 SEM (bars) values, in percentages of
bound [35S]GTPgS in the absence of agonist on bacterial mem-
branes pretreated with 200 nM purified Gbg subunits, of three
independent experiments performed in duplicate.
TABLE 2. Agonist potencies in stimulating [35S]GTPgS
binding, measured as EC50 values
EC50 (nM)
DAMGO Endomorphin-1 Endomorphin-2 Morphine
hMOR–Gao1 816 25 466 15 616 6 536 7
hMOR–Gai2 1106 38 286 3 1136 39 186 4
[35S]GTPgS was used at a fixed concentration of 1 nM. Agonists
were added at various concentrations ranging from 93 10210 to 1025
M, in the presence of 200 nM Gbg subunits. Data are mean6 SEM
values of three independent experiments performed in duplicate.
FIG. 5. Maximal stimulation of [35S]GTPgS binding. Data are
mean 6 SEM (bars) values, in percentages of bound [35S]GTPgS
in the presence of 1025 M agonist on bacterial membranes
pretreated with 200 nM purified Gbg subunits, of two or three
independent experiments performed in duplicate. Reversal of
agonist-stimulated [35S]GTPgS binding was performed in the
presence of 5 3 1025 M naloxone.
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of the hMOR fused at its C terminus to either one of two
Ga subunits, Gao1 and Gai2, previously identified as
possible coupling partners (Laugwitz et al., 1993; Chan
et al., 1995; Murthy and Makhlouf, 1996). TheE. coli-
expressed receptor–Ga chimeras were functional, as
shown by the facts that the presence of the fused Ga
subunit restored high-affinity agonist binding and that
agonists were able to stimulate [35S]GTPgS binding at
the Ga subunit fused to the receptor C terminus. Recon-
stitution of coupling between the fused receptor and the
Gao1 and Gai2 subunits confirmed that these two sub-
types of Ga subunits are involved in signaling through
the hMOR. It is interesting that the pharmacological
characterization of the two individual receptor–Ga cou-
ples provided evidence that the affinity of the receptor
for the different agonists depended on the nature of the
Ga subunit to which it is coupled. DAMGO and endo-
morphin-1 and -2 showed a higher affinity for the
hMOR–Gai2 fusion protein, suggesting that these ago-
nists stabilize the receptor population that is coupled to
Gai2 better than the population that coupled to Gao1.
Morphine showed no such preference, indicating that its
binding to the hMOR has different requirements than
that of the other three agonists. The observed differences
in agonist recognition by the receptor fused to one or to
the other Ga subunit, in the presence or in the absence of
Gbg dimers, may serve as a means to characterize the
multiple states the receptor is able to adopt as a function
of its interaction partners.
Receptor–Ga fusion proteins have become an increas-
ingly popular tool for the study of GPCR–G protein
signaling pathway. Theb2-adrenergic receptor fused to
its coupling partner Gas was able to restore adenylyl
cyclase activation in a cell line defective in endogenous
Gas (Bertin et al., 1994). This first report of receptor–Ga
fusion functionality has been followed by several studies
of receptor–G protein interactions where the receptor and
the Ga were expressed from a chimeric open reading
frame (for review, see Seifert et al., 1999a; Milligan,
2000).
One major inconvenience of eukaryotic expression
systems, commonly used for pharmacological studies, is
the simultaneous presence within the cell of endogenous
G protein subtypes, resulting in a potentially high back-
ground. This issue remains relevant for studies of recep-
tor–Ga chimeras. In the case of thea2-adrenergic recep-
tor–Gai1 fusion protein, it has been shown that receptor
interactions are not restricted to the tethered Ga subunit,
but they can also occur with endogenous G proteins
(Burt et al., 1998). Different means were used so far to
lower the background signal. Receptor–Ga chimeras
were expressed in insect cells where the receptor was
known not to couple effectively to the endogenous G
proteins (Seifert et al., 1998). Also, a mutant Ga subunit
resistant to pertussis toxin treatment was used to allow
for selective inactivation of the endogenous Gi/o (Wise
and Milligan, 1997). The first strategy is not always
applicable as coupling to insect G proteins has been
shown to occur with many GPCRs expressed in insect
cells (Van den Broeck, 1996). Also, Ga mutants resistant
to toxin treatment are not always available, and an ac-
curate assessment of G protein behavior may require the
use of native proteins. Bacteria lack a G protein-medi-
ated signal transduction pathway; thus, the coupling
specificity of anE. coli-expressed GPCR may be studied
in an environment devoid of interfering endogenous G
proteins or regulatory elements such as regulators of G
protein signaling, GPCR kinases, and arrestins.
hMOR–Ga fusion proteins were expressed inE. coli
at levels compatible with pharmacological studies, al-
though low (;30 receptor sites per cell, or 0.5 pmol/mg
of membrane protein). The hMOR fused at its C terminus
to either Gao1 or Gai2 bound the antagonist diprenor-
phine with high affinity, indicating, as expected, that the
presence of the Ga subunit had no bearing on its antag-
onist binding characteristics.
Absolute values drawn from experiments with recep-
tor–Ga fusion proteins are probably biased as a conse-
quence of the constrained proximity between the recep-
tor and the Ga subunit. Thus, they do not necessarily
accurately describe the behavior of receptors and G pro-
teins in vivo. Further experiments, involving a compar-
ison between receptor–Ga constructs and receptors re-
constituted with purified Ga subunits, are necessary to
ascertain to what extent tethering of the Ga subunit bears
on its receptor-coupling properties. Previous reports of
reconstitution studies of them-opioid receptor with pu-
rified Ga subunits (Ueda et al., 1988; Fan et al., 1995;
Gaibelet et al., 1999) do not determine pharmacological
profiles of the receptor in the presence of the different
Ga subunits but merely assess the general capacity of
this receptor to couple to the members of Gai/o family of
G proteins. Yet, so far experimental data have validated
the use of receptor–Ga fusion constructs as models for
the functional studies of GPCRs (Milligan, 2000). More-
over, our conclusions are based on a comparative anal-
ysis of results using two different, similarly constructed,
hMOR–Ga fusion proteins; this approach can be ex-
pected to minimize the impact of the physical constraint
of the two partners on the pharmacological properties of
the receptor.
It can be estimated (Fig. 5; see Results) that only a
fraction of the total ligand binding sites also represents
functional [35S]GTPgS binding sites. This could be at-
tributed to proteolytic degradation of the MBP–
hMOR–Ga fusion proteins, with the Ga subunit being
probably cleaved off. A different proteolytic rate be-
tween hMOR–Gao1 and hMOR–Gai2 could bias the
results of ligand affinity and efficacy determination at the
two fusion proteins. However, the fraction of
[35S]GTPgS binding sites of the total number of ligand
binding sites is not significantly different between the
two receptor–Ga fusion proteins. Moreover, data con-
cerning agonist stimulation of [35S]GTPgS binding are
represented as percentages of the background
[35S]GTPgS binding at each hMOR–Ga fusion protein.
Thus, results are independent of the expression level of
each fusion protein.
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According to the ternary complex model describing
receptor–G protein interactions (Leff et al., 1997), effi-
cient coupling of the receptor to its cognate G protein
manifests itself as high-affinity agonist binding and as
enhanced GDP–GTP exchange at the Ga subunit. This
latter may be estimated in terms of [35S]GTPgS binding
on Ga (Befort et al., 1996). We checked whether the
presence of Gao1 and Gai2 fused downstream of the
hMOR was able to induce high-affinity binding of sev-
eralm-selective agonists. In the presence of purified Gbg
subunits, high-affinity binding of all four agonists tested
was achieved with both fusion constructs. Both fused Ga
subunits kept their capacity of [35S]GTPgS binding, fur-
ther stimulated by agonists, as shown by the dose–
responsecurves in the presence of increasing concentra-
tions of the ligand. These results confirm that the hMOR
is capable of effective coupling to both Gao1 and Gai2,
as previously suggested by studies performed on heter-
ologously expressed hMORs in mammalian cells (Laug-
witz et al., 1993; Chan et al., 1995; Murthy and Makhl-
ouf, 1996).
It is known that the presence of Gbg dimers promotes
coupling between the receptor and the catalytic Ga sub-
unit. Previous reports showed that Gbg subunits were
needed for coupling to occur in vitro in reconstituted
systems, for instance, betweenE. coli-expressed A1
adenosine receptor (Jockers et al., 1994). Our results tend
to support the favorable effect of Gbg dimers on recep-
tor–Ga coupling. After reconstitution with Gbg, high-
affinity binding for endomorphins was restored at
hMOR–Gao1, andKi values of high-affinity binding sites
for DAMGO and endomorphins were decreased at
hMOR–Gai2 (Table 1). Yet, coupling to Ga in the ab-
sence of Gbg dimers was surprisingly effective as high-
affinity agonist binding was apparent in all cases except
for the binding of endomorphins at hMOR–Gao1 (Table
1). This supports the notion that the high-affinity state of
the receptor can also be stabilized through interaction
with the Ga subunit alone. Presumably the covalent link
engineered between the receptor and Ga reduces the
degrees of freedom in the mobility of the Ga subunit and
thus increases coupling efficacy, accounting in part for
these results.
Yet, in some cases tethering of the Ga subunit to the
receptor does not compensate for the absence of Gbg:
Addition of Gbg dimers to Gbg-depleted membranes
containing the A1-adenosine receptor fused to Gai1 pro-
moted high-affinity agonist binding (Waldhoer et al.,
1999). It is likely that some variability exists, related to
the specific ligand–receptor–Ga triad under study. Our
results support this hypothesis, providing evidence that
the affinities of the different agonists tested were differ-
ently sensitive to the presence of Gbg. For instance, on
addition of Gbg, the affinity of morphine at hMOR–Gai2
remained virtually unchanged, whereas the affinities of
DAMGO and endomorphins were significantly increased
(Table 1).
It has been already shown that different Ga subunits
have different affinities for GDP or for GTP; Gao1 has a
higher basal rate of nucleotide exchange than Gi2 (Fer-
guson et al., 1986). Thus, we cannot rule out that the
apparently higher constitutive activity of the hMOR–
Gao1 fusion protein (Fig. 3) may be entirely due to
different affinity constants for guanine nucleotides. At
the same time, this prevents comparison between maxi-
mal levels of [35S]GTPgS binding induced by one ago-
nist at the two receptor–Ga fusion proteins. Neverthe-
less, it is relevant to compare intrinsic activities and
efficacies of different agonists at each receptor–Ga chi-
mera. In the presence of Gbg dimers, all agonists tested
were equally potent in stimulating [35S]GTPgS binding
at hMOR–Gao1. At hMOR-Gai2, under the same condi-
tions, endomorphin-1 and morphine were significantly
more potent than DAMGO and endomorphin-2 (Table
2). No correlation was found betweenKi and EC50 values
of the different agonists, supporting the view that agonist
binding and agonist-induced activation of the G protein
are two distinct processes.
Endomorphin-1 and -2 have been reported to be partial
agonists of them-opioid receptor, in native tissues as
well as in transient expression systems (Alt et al., 1998;
Sim et al., 1998). In the presence of Gbg dimers, no
evidence of partial agonist behavior was found in our
experiments. All agonists tested induced similar maximal
[35S]GTPgS binding levels (Fig. 5).
The main outcome of the present study is that activi-
ties of different agonists were differently sensitive to the
nature of the Ga subunit that was attached to the receptor
and to the presence or absence of Gbg. DAMGO and
endomorphins, but not morphine, showed a higher affin-
ity for hMOR–Gai2 than for hMOR–Gao1. The rank
orders of agonist potencies in stimulating [35S]GTPgS
binding at hMOR–Gao1 and hMOR–Gai2 did not coin-
cide. These discrepancies depict a complex picture of the
interactions within the triad ligand–receptor–G protein.
Our results are in agreement with the hypothesis that the
receptor adopts different conformations depending on
the nature of the Ga subunit to which it is coupled (Leff
et al., 1997). There is increasing evidence in support of
the notion that G protein type influences agonist efficacy
(Seifert et al., 1999b; Yang and Lanier, 1999). In vivo
experiments of selective down-regulation of different Ga
subunits by antisense oligodeoxynucleotide treatment
(Sanchez-Blazquez et al., 1999) showed that agonists
activate with different efficacies the G proteins regulated
by them receptor. In particular, an antisense probe tar-
geting Gai2 blocked the analgesic effects of DAMGO,
endomorphin-2, and morphine, whereas antisense treat-
ment directed against Gao1 had little or no effect on
opioid-induced analgesia. Our results, showing a higher
affinity of DAMGO and endomorphins for the hMOR–
Gai2 complex than for hMOR–Gao1, suggest that this is
due to preferential binding of these agonists to receptors
coupled to Gai2. A different mechanism probably applies
in the case of morphine, which displayed similar affini-
ties for the two receptor–Ga complexes.
The concept of the simultaneous existence of multiple
possible receptor conformations, selectively favored by
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interaction with different agonists and G proteins, might
help explain the phenomenon of differential agonist reg-
ulation of them-opioid receptor. It has been found that
prolonged exposure of them-opioid receptor to the opi-
oid agonists methadone and buprenorphine, but not to
DAMGO or morphine, abolished the ability of opioids to
inhibit adenylyl cyclase (Blake et al., 1997). Distinct
differences in protein kinase A-mediated phosphoryla-
tion pattern of them-opioid receptor were generated by
morphine and related alkaloids as compared with
DAMGO and other enkephalin analogues (Chakrabarti
et al., 1998). A peculiar behavior has been described for
morphine, which is unable to induce internalization of
the m-opioid receptor (Sternini et al., 1996). It has been
shown that morphine binding at the receptor favors a
receptor conformation that interacts ineffectively with
b-arrestin and subsequently with clathrin (Whistler and
von Zastrow, 1998; Zhang et al., 1998). It is intriguing
that in our experiments morphine behaved distinctly
from the other agonists tested: Its binding to the fused
receptor was little influenced by the nature of the Ga
subunit or by the presence or absence of Gbg dimers.
Our results converge toward the hypothesis of a di-
versity of possible receptor conformations, differently
able to interact productively with ligands, G proteins, or,
possibly, regulators of signaling. At the same time, the
results prove thatE. coli-expressed receptor–Ga fusion
proteins are functional and apt for reconstitution with
purified Gbg subunits. As the prokaryotic environment
allows control over the receptor and G protein subtype
composition of the experimental setup,E. coli-expressed
receptor–Ga chimeras should prove a useful tool in
dissecting the interplay of elements involved in G pro-
tein-mediated signal transduction.
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